Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Capecitabine Following Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Patients
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Capecitabine (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms CIBOMA
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.